Changes in Amylin and Amylin-Like Peptide Concentrations ana (β-Cell Function in Response to Sulfonylurea or Insulin Therapy in NIDDM

OBJECTIVE Amylin, a secretory peptide of fi-cells, is the constituent peptide of islet amyloid, which is characteristic of NIDDM, and changes in amylin secretion in response to therapies may influence the rate of production of islet amyloid. The primary objective of this study was to determine whether therapy with sulfonylurea or basal insulin in NIDDM would alter amylin secretion in a way that might affect the formation of islet amyloid. RESEARCH DESIGN AND METHODS In a randomized crossover design, eight subjects with NIDDM underwent diree 8-week periods of therapy with diet alone, sulfonylurea, or exogenous basal insulin, with evaluation of amylin, amylin-like peptide (ALP), and glucose and C-peptide concentrations, both during fasting and after a standard breakfast. Changes in (β-cell function (%β) were assessed, in the basal state by homeostasis model assessment (HOMA) and in the stimulated state by hyperglycemic clamps. Seven nondiabetic control subjects each underwent a meal profile and hyperglycemic clamp. RESULTS Both sulfonylurea and insulin therapy reduced basal glucose concentrations compared with diet alone, but neither reduced the increased postprandial glucose increments. Both sulfonylurea and insulin therapy increased basal %β, assessed by HOMA, but only sulfonylurea increased the second-phase C-peptide responses to the hyperglycemic clamp. Sulfonylurea increased time-averaged mean postprandial amylin and ALP concentrations compared with diet alone (geometric mean [1-SD range] for amylin, 4.9 [2.0–11.8] vs. 3.0 [1.4–6.2] pmol/1, P = 0.003; for ALP, 16.4 [8.5–31.7] vs. 10.1 [4.9–20.8] pmol/1, P = 0.001). Insulin therapy reduced basal ALP concentrations compared with diet alone (2.9 [1.5–5.6] vs. 6.0 [2.6–13.6] pmol/1, P = 0.03), but had no effect on postprandial concentrations of amylin (3.0 [1.3–6.5] pmol/1) or ALP (10.0 [5.5–18.1] pmol/1). CONCLUSIONS By increasing postprandial concentrations of the constituent peptides of islet amyloid, sulfonylurea therapy might increase the rate of deposition of islet amyloid and thereby accelerate the decline of %β in NIDDM, compared with diet therapy alone.

[1]  D. A. Trainor,et al.  Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. , 1996, Clinical chemistry.

[2]  A. Clark,et al.  Islet amyloid in type 2 (non‐insulin‐dependent) diabetes , 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[3]  J. Levy,et al.  U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.

[4]  K. Cusi,et al.  Safety and Efficacy of Normalizing Fasting Glucose With Bedtime NPH Insulin Alone in NIDDM , 1995, Diabetes Care.

[5]  R. Holman,et al.  UK Prospective Diabetes Study (UKPDS) XI: Biochemical Risk Factors in Type 2 Diabetic Patients at Diagnosis Compared with Age‐matched Normal Subjects , 1994, Diabetic medicine : a journal of the British Diabetic Association.

[6]  P. Westermark Amyloid and polypeptide hormones: What is their interrelationship? , 1994 .

[7]  A. Clark Islet amyloid: an enigma of type 2 diabetes. , 1992, Diabetes/metabolism reviews.

[8]  D. Kelley,et al.  Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. , 1992, The New England journal of medicine.

[9]  Michael W. Schwartz,et al.  Evidence of Cosecretion of Islet Amyloid Polypeptide and Insulin by β-Cells , 1990, Diabetes.

[10]  K. Polonsky,et al.  Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus. , 1989, The Journal of clinical endocrinology and metabolism.

[11]  D. Matthews,et al.  Unbiased and Flexible Iterative Computer Program to Achieve Glucose Clamping , 1989, Diabetes Care.

[12]  E. Kraegen,et al.  Physiological Importance of Deficiency in Early Prandial Insulin Secretion in Non-Insulin-Dependent Diabetes , 1988, Diabetes.

[13]  R. Turner,et al.  Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. W. Hayden,et al.  Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. , 1987, The American journal of pathology.

[15]  R. Hamman,et al.  The Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus , 1985, Diabetes.

[16]  W. J. Andrews,et al.  Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal , 1984, Diabetes.

[17]  S. Aronoff,et al.  Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type II diabetics. , 1982, The Journal of clinical endocrinology and metabolism.